Study of GSK5458514 alone or with other drugs for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, GSK5458514, either alone or with other cancer treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if the drug can slow down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- You must have prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy.
- You must have tried at least one type of hormone therapy and up to two types of chemotherapy that no longer work.
- You must be willing to use effective contraception and not donate sperm during the study and for 195 days after the last dose.
- You must have tumor tissue available (from a recent or past biopsy) for testing.
- You must not have certain other cancers, serious infections, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental new drug (GSK5471713) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It is for people who have already tried certain hormone treatments and chemotherapy.
This trial tests a new drug called JNJ-98768111 for people with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The drug may help shrink or slow the cancer, and participating could give you access to a promising new treatment.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new drug, GLR2037, in men with metastatic prostate cancer that has spread to bones or soft tissues and is no longer responding to hormone therapy. The goal is to see if it is safe and how well it works.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This trial tests a new drug, HSK46575, for men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy and chemotherapy. The goal is to see if it can help slow the cancer's growth.
Hear when a new Neoplasms, Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.